Next Arc Research

Not logged in? You're viewing the Free tier. Join for free or log in to access your membership content.
Disclaimer: This content is for informational and educational purposes only and should not be construed as financial or investment advice. Always do your own research and consult a licensed financial advisor before making investment decisions.
Disclosure: The author holds a long position in BFLY.
← Back to Free Index

BFLY

Analysis as of: 2026-08-14
Butterfly Network, Inc.
Butterfly Network sells handheld ultrasound devices, cloud workflow software, and AI-enabled imaging tools to clinicians, health systems, educators, and embedded partners.
ai hardware healthcare medical devices software
On Yahoo Finance ...
Jump to: Summary • Analysis • Opportunity • Risk • Trends • LE Structure • Third Party Analyst Consensus

Summary

From handheld device to imaging workflow platform
The upside case is a shift from selling probes to owning more of the clinical workflow and selectively licensing the chip stack. The catch is that government, home-care, and partner proof points must arrive before valuation gravity does.

Analysis

Thesis
Butterfly can roughly double equity value by 2031 if it turns a strong handheld ultrasound franchise into a higher-margin regulated workflow and embedded-chip business; AI expands who can scan, but the real win is owning verification, archive, and partner distribution rather than interpretation alone.
Last Economy Alignment
Cheaper cognition should expand ultrasound usage and make Butterfly’s probe-plus-workflow stack more useful, but it is not the sole bottleneck owner. Its hardware, compliance, and workflow hooks matter, yet large imaging vendors and vendor-neutral AI can still compress software differentiation.
Upgrade to Allocator to also access: Thesis Critique

Opportunity Outlook

Average Implied 5-Year Multiple
2.2x (from 5 most recent analyses)
Reasoning
The upside does not require Butterfly to dominate ultrasound. It requires the company to keep compounding core probe adoption, attach more workflow software, and prove Embedded, government, and home-care channels are real businesses rather than pilot stories. If that happens, the market can still reward it as a differentiated medtech-plus-software asset, but the rerating is capped because the stock already embeds meaningful optimism.
Upgrade to Allocator to also access: Simplified Opportunity Explanation

Risk Assessment

Overall Risk Summary
The main risk is not product validity but value capture. Butterfly must prove that compliance, workflow, and Embedded convert from promising add-ons into durable revenue engines before large imaging vendors, slower procurement, or valuation gravity turn it back into a premium handheld device story.
Upgrade to Allocator to also access: Tech Maturity Risk Score, Adoption Timing Risk Score, Moat Strength Risk Score, Capital Needs Risk Score, Regulatory Risk Score, Execution Risk Score, Concentration Risk Score, Unit Economics Risk Score, Valuation Risk Score, Macro Sensitivity Risk Score

Last Economy Structure

AI Industrial Score
0.35
They control a real physical choke point: the probe and chip that enable the scan, then add software that helps store, review, and govern it. AI should help more people use ultrasound, but big imaging vendors and generic AI can still weaken the software layer if Butterfly fails to lock in workflow and compliance.
Upgrade to Reader to also access: Score Decomposition, Confidence Level
Upgrade to Allocator to also access: Obsolescence Vectors, Pricing Fragility
Upgrade to Reader to also access: Constraint Benefit Score, Obsolescence Risk Score

Third Party Analyst Consensus

12-Month Price Target
$8.06
Upgrade to Reader to also access: Bull Case, Base Case, Bear Case